AUTHORS
Saharsh Narayanam, Emma Pappano, BS2, Archana Wath3, Mark T. T Gladwin, MD4, Victor Gordeuk, MD5, Santosh L Saraf, MD6, Dipty Jain, MBBS7
AFFILIATIONS
1 University of Illinois Chicago, Chicago, Illinois, United States
2 University of Illinois Chicago, Chicago, Illinois, United States
3 Government Medical College and Hospital, Nagpur, India
4 University of Maryland, Baltimore, Maryland, United States
5 University of Illinois Chicago, Chicago, Illinois, United States
6 University of Illinois Chicago, Chicago, Illinois, United States
7 Government Medical College and Hospital, Nagpur, India
ABSTRACT
India has the second highest global prevalence and the third highest birthrate of people with sickle cell disease (SCD). While SCD was believed to be milder in this region due to coinheritance of haplotypes with higher fetal hemoglobin (Hb) concentrations, more recent evidence suggests that rates of acute and chronic complications may be similar to other geographic regions where SCD is common. Chronic kidney disease (CKD) is among the most frequent complications observed in people with SCD and predicts substantial morbidity and early mortality. The burden of CKD is not well understood in patients with SCD from India. To address this, we investigated the prevalence and clinical variables associated with kidney dysfunction in a large cohort of patients with SCD from Nagpur, India, and compared the burden of kidney disease to two cohorts representing patients with SCD from the US and UK, PUSH and Walk-PHaSST.
We evaluated the prevalence of kidney dysfunction in a cohort of 331 children and adults with hemoglobin SS genotype SCD treated at the Government Medical College (GMC) in Nagpur, Maharashtra, India. Baseline clinical and laboratory data were collected at the time of recruitment and compared to data from 743 children and adults with hemoglobin SS genotype SCD enrolled in the PUSH (NCT00495638) and Walk-PHaSST (NCT00492531) cohorts. Estimated glomerular filtration rate (eGFR) was calculated using the revised Schwartz (<18 years) and 2021 CKD-EPI (≥18 years) equations. Urine albumin-to-creatinine ratio (uACR) was available in 103 (31%) and 292 (39%) SCD patients from the GMC and PUSH/Walk-PHaSST cohorts, respectively. We tested the association of variables with eGFR and uACR using linear regression analysis in the GMC cohort, adjusting for age, sex, and hydroxyurea use. We tested the comparisons of abnormal kidney function (eGFR < 90 mL/min/1.73m2, uACR ≥ 30 mg/g) by cohort (GMC vs. PUSH/Walk-PHaSST) using logistic regression, adjusting for age, sex, and hydroxyurea use. Mean ± standard error values are provided for β values.
The median age of the GMC cohort was 11 (interquartile range [IQR], 7-17) years old, 144 (44%) were female, and 186 (56%) were on hydroxyurea. The median eGFR was 121 (IQR, 91-156) mL/min/1.73m2 and uACR was 17 (IQR, 9-39) mg/g. In the GMC cohort, older age was associated with a higher eGFR (β 1.97±0.33; P<0.001) and a higher uACR (β 0.03±0.01; P=0.013). Systolic blood pressure was independently associated with kidney dysfunction for both lower eGFR (log-transformed β -67.9±35.8; P=0.059) and higher uACR (log-transformed β 3.19±1.17; P=0.008), adjusting for age, sex, and hydroxyurea. We did not observe an association between kidney function and Hb concentration or Hb F% in the GMC cohort.
Next, we compared the prevalence of kidney dysfunction between the SCD patients from the GMC cohort and the PUSH/Walk-PHaSST US and UK cohorts. The median age of the GMC cohort was significantly younger (11 vs. 27 years), and hydroxyurea use was more common (56% vs. 45%) compared to the PUSH/Walk-PHaSST cohorts (P<0.001), while sex distribution was relatively similar (female 44% vs. 50%). Abnormal kidney function, based on eGFR < 90mL/min/1.73m2, was present in 24% (79/331) and 15% (115/743) of the GMC and PUSH/Walk-PHaSST cohorts, while uACR ≥ 30 mg/g was observed in 35% (36/103) and 51% (150/292) of the GMC and PUSH/Walk-PHaSST cohorts, respectively. After adjusting for age, sex, and hydroxyurea, the odds of an abnormal eGFR were higher in the GMC versus PUSH/Walk-PHaSST cohorts (OR 6.1, 95% CI: 3.8-9.6; P<0.001), while the odds of an abnormal uACR was not statistically significant between the two groups (P=0.4).
In conclusion, we demonstrate that the phenotype of SCD in India is more aggressive than previously assumed based on the burden of CKD. We show that there is a high prevalence of reduced eGFR and elevated uACR and that the risk of these abnormalities is at least similar to SCD patients from the US and UK. Systolic blood pressure was an independent predictor for kidney dysfunction in the GMC cohort and further investigation into the blood pressure thresholds and management approaches in this cohort are needed. Based on the high prevalence of CKD, future studies investigating genetic risk modifiers for kidney dysfunction in this vulnerable patient population are warranted.
DISCLOSURES
Saharsh Narayanam: No relevant conflicts of interest to declare.